Inaugural lectures

Welcome to HiLIFE

HiLIFE Helsinki Institute of Life Science is happy to introduce newly appointed unit directors. Come and hear their visions on cutting edge research and innovation!

HiLIFE Lectures Wednesday 3 October 2018 at 15:00 – 16:30
Lecture hall 1, Biomedicum Helsinki (Haartmaninkatu 8)

Snacks and refreshments afterwards. Welcome!

REGISTER HERE

15:00 Opening words, Vice Rector Paula Eerola, Chair of the HiLIFE Board 

15:15 Lectures by newly appointed directors (chair: Tomi Mäkelä, HiLIFE director)

  • Bi­o­tech­no­logy – Driv­ing a bet­ter fu­ture from crop fields to clin­ics, Olli Silvennoinen, Institute of Biotechnology, HiLIFE
  • The ge­net­ics of com­mon dis­ease and the fu­ture of in­di­vidu­al­ized medi­cineMark Daly, Institute for Molecular Medicine Finland FIMM, HiLIFE
  • Understanding the human brainJari Koistinaho, Neuroscience Center, HiLIFE

16:30 Refreshments

Olli Silvennoinen started as director of the Institute of Biotechnology at full speed in May 2018. He has made groundbreaking discoveries in immunology and has developed innovative ways to lead research centres in Finland and internationally. His inaugural lecture is titled Biotechnology – Driving a better future from crop fields to clinics.

Olli has wide leadership experience e.g. from the Institute of Medical Technology at the University of Tampere, and the Biocenter Finland where he has acted as the Chair of the Board and the Stem Cells and Biomaterials Network. Silvennoinen has spent several years in the United States at St Jude’s Children's Research Hospital, UCSF, and Yale University, and in China as a visiting professor of the Tianjin Medical School.

Mark Daly was recruited from the Broad Institute of MIT and Harvard and Massachusetts General Hospital to lead the Institute for Molecular Medicine Finland (FIMM). Mark is a distinguished scientist who has made major contributions to human genetics and genomics during his 20-year career. His inaugural lecture is titled The genetics of common disease and the future of individualized medicine.

Mark Daly has made seminal discoveries in understanding the details of the structure of the human genome and developing software tools to analyse the impact of genetic variations on various diseases, with special interest in autism, ADHD and other psychiatric diseases as well as inflammatory diseases. He has over 400 scientific publications, and in his new job he will be the top cited scientist in Finland with over 130 000 citations.

Jari Koistinaho was recruited to lead the Neuroscience Center from the University of Eastern Finland where he was Professor of Stem Cell Research and Professor of Pharmacology.  He was trained as physician at University of Tampere and did his doctorate on aging there. His inaugural lecture is titled Understanding the human brain.

Koistinaho has worked abroad for over seven years in total at the US National Institute of Health, University of California San Francisco, Stanford University, Indiana and Purdue Universities, and Karolinska Institute. Koistinaho is also the founder of three spin-off companies: Cerebricon Ltd acquired by Charles River Discovery Research Services 2009; Medeia Therapeutics Ltd 2006, and Aranda Pharma Ltd 2015.